Skip to content
FDA-approvedFor Wet✓ Free to read

HMG

Also called Human Menopausal Gonadotropin / Menotropin

When one fertility signal is not enough, this shot delivers both at once to make sperm or grow an egg.

Updated 03 May 2026Read 4 minBacked by 60 studies
The quick version
What it is
A shot giving both LH and FSH signals
Is it FDA-approved?
Yes, for fertility and IVF
How strong is the proof?
Very strong: about 60 years of use
How you take it
A shot, several times a week
Typical result
Boosts sperm success to ~80–90% when added to hCG
Biggest catch
Pricey, needs a fertility clinic, and 'RUO hMG' is almost always fake

Any word with a dotted underline is a science word — tap it for a plain-English meaning.

In plain words.

HMG stands for human menopausal gonadotropin. It is also called menotropin. Brand names are Menopur and Repronex.

Your body uses two signals for fertility: LH and FSH. hCG copies only LH. hMG gives you both LH and FSH at the same time. The FSH part is the piece that drives sperm production and egg growth.

The original drug is purified from the urine of women past menopause. That sounds odd, but their urine is naturally rich in these hormones. It is made at industrial scale. There is now also a lab-made version.

It is and has been used for about 60 years.

What people use it for.

People use hMG for fertility when the FSH signal is needed.

  • Men trying to have kids. Some men on TRT find that hCG alone does not restore sperm. Adding hMG gives the missing FSH signal.
  • IVF. It helps the ovaries grow eggs during an IVF .
  • Low hormone-signal infertility. For men whose brains do not send enough fertility signal, hMG plus hCG can start sperm production.

It is not a libido or "boost" . It is a fertility drug.

Does it actually work?

Yes, and the proof is strong.

Here is the key comparison. In men with low hormone signals, hCG alone gets sperm going in about 40–60% of cases over 6 to 24 months (Liu 2009). When hCG alone does not work and you add the FSH side (hMG), success jumps to about 80–90% (Warne 2009).

The smart rule from the studies: add hMG only if there is still zero sperm after about 6 months on hCG alone. Not on day one (hCG often works alone, and hMG is pricey), and not "just wait longer." That 6-month checkpoint is the decision point.

what you’ve probably heard.

The claims floating around online, and how true they actually are.

hMG works better than hCG for fertility.

half true

It is not better, it is an add-on. hCG alone restarts sperm in about 40 to 60% of low-signal men. You only add hMG when there is still zero sperm after about 6 months on hCG.

hMG and hCG are basically the same shot.

no

Not the same. hCG only copies the LH signal, while hMG adds FSH, the piece that actually drives sperm and egg growth. That extra FSH is why adding it can push success up to roughly 80 to 90%.

Start hMG day one alongside hCG for the best shot.

not quite

The studies say wait. hCG often works on its own, and hMG is pricey, so the smart move is to add it only after about 6 months with zero sperm. That checkpoint is the whole game.

You can buy research-grade hMG cheap online.

myth

Real hMG is purified from urine at industrial scale, so a research-chemical vendor physically cannot make it. Vials sold as ' hMG' are almost always pure FSH or LH mislabeled.

How you take it.

You take it as a shot, several times a week. It can go under the skin or into the muscle.

A common vial is 75 . Men using it for fertility might use a few vials a week, often paired with hCG. IVF uses a clinic-set protocol that runs higher.

It comes as a powder you mix before use. Once mixed, it goes bad fast, within about 7 to 10 days even in the fridge. A fertility clinic guides the exact schedule.

What to watch out for.

The common stuff

Most people tolerate it. The main issue is that it is several shots a week, which takes commitment.

The serious stuff

  • Do not use it if you have a hormone-sensitive cancer or an unexplained mass.
  • In IVF, it can rarely cause OHSS. That is when the ovaries get overworked and swollen. It needs a doctor right away.

This is a supervised fertility drug, not something to "try" on your own. The clinic that made the diagnosis is the one who should be dosing it.

Where people get it.

Here are the lanes, safest to riskiest.

  • Brand (Menopur, Repronex). Real pharmacy product with a prescription. About $80–$150 per 75 vial. A month of male fertility use runs around $300–$900; a full IVF is $1,500 or more. Safest.
  • . Rare, because the FSH-plus-LH mix is hard to make. About $250–$400 a month when you can find it.
  • Research-only (): the big warning. Walk away. Real hMG is purified from urine at industrial scale. A research-chemical vendor cannot make it. " hMG" is almost never the real product. It is often pure FSH or pure LH mislabeled.
  • Gray-market: there is no real for hMG either.

Our honest take.

This one has a real job, and it is a narrow one: getting the FSH signal into a man whose hCG alone never restarted sperm, or growing eggs in an IVF .

Let a reproductive doctor prescribe, supply, and monitor it. For a man, the cleanest path is usually to try hCG first and add hMG only if there is still zero sperm after about 6 months. That checkpoint is the whole game.

Where it goes wrong is the buy. " hMG" is almost always a lie: the real drug is purified from urine at industrial scale, so a research-chemical vendor physically cannot make it. What ends up in that vial is usually pure FSH or pure LH wearing the wrong label. If hMG is right for you, the clinic is the only honest door.

The studies behind this.

We read the research so you don't have to. Here's where the facts on this page come from.

  1. 01Capolupo A, et al. Analytical Investigation of the Profile of Human Chorionic Gonadotropin in Highly Purified Human Menopausal Gonadotrophin Preparations. International journal of molecular sciences. 2024;25(17). PMID: 39273352.
  2. 02Li J, et al. Human menopausal gonadotropin (HMG) combined different doses of letrozole for treating anovulatory infertility in patients with polycystic ovary syndrome: a randomized controlled trial. Journal of assisted reproduction and genetics. 2025;42(6):1895-1906. PMID: 40193016.
  3. 03Li HQ, et al. Retrospective analysis: The application of human menopausal gonadotropin combined with letrozole for IUI in patients undergoing artificial insemination by husband due to unexplained or mild male factors. Frontiers in endocrinology. 2022;13:1038433. PMID: 36605946.
  4. 04Deeks ED. Highly Purified Human Menopausal Gonadotropin (Menopur(®)): A Profile of Its Use in Infertility. Clinical drug investigation. 2018;38(11):1077-1084. PMID: 30264288.
  5. 05Levi Setti PE, et al. Human recombinant follicle stimulating hormone (rFSH) compared to urinary human menopausal gonadotropin (HMG) for ovarian stimulation in assisted reproduction: a literature review and cost evaluation. Journal of endocrinological investigation. 2015;38(5):497-503. PMID: 25480425.
  6. 06Korucu DG, et al. Comparing highly purified human menopausal gonadotropin and recombinant follicle stimulating hormone in poor ovarian reserve patients undergoing intracytoplasmic sperm injection. Ceska gynekologie. 2024;89(6):469-474. PMID: 39800543.
  7. 07Fischer L, et al. Luteinizing hormone supplementation with human menopausal gonadotropin versus low dose human chorionic gonadotropin during ovarian stimulation does not affect live birth rates after fresh and frozen embryo transfer. The journal of obstetrics and gynaecology research. 2024;50(10):1935-1944. PMID: 39245464.
  8. 08Büchter D, et al. Pulsatile GnRH or human chorionic gonadotropin/human menopausal gonadotropin as effective treatment for men with hypogonadotropic hypogonadism: a review of 42 cases. European journal of endocrinology. 1998;139(3):298-303. PMID: 9758439.
  9. 09Berker B, et al. Human Menopausal Gonadotropin Commenced on Early Follicular Period Increases Live Birth Rates in POSEIDON Group 3 and 4 Poor Responders. Reproductive sciences (Thousand Oaks, Calif.). 2021;28(2):488-494. PMID: 32833190.
  10. 10Abdel-Salam M, et al. The possible effect of human menopausal gonadotropin on the audio-vestibular system. Auris, nasus, larynx. 2018;45(6):1166-1172. PMID: 29747963.
  11. 11Kemeter P, et al. Ovarian stimulation with clomiphene and/or human menopausal gonadotropin (HMG) for in vitro fertilization (IVF) and embryo transfer (ET). Experientia. 1985;41(12):1502-7. PMID: 3935476.
  12. 12Chen LH, et al. Supplementation with human menopausal gonadotropin in the gonadotropin-releasing hormone antagonist cycles of women with high AMH: Pregnancy outcomes and serial hormone levels. Taiwanese journal of obstetrics & gynecology. 2021;60(4):739-744. PMID: 34247817.
  13. 13Fishel SB, et al. Implantation, abortion, and birth after in vitro fertilization using the natural menstrual cycle or follicular stimulation with clomiphene citrate and human menopausal gonadotropin. Journal of in vitro fertilization and embryo transfer : IVF. 1985;2(3):123-31. PMID: 3932567.
  14. 14Kaplan PF, et al. Subcutaneous human menopausal gonadotropin administration for controlled ovarian hyperstimulation with intrauterine insemination cycles. American journal of obstetrics and gynecology. 2000;182(6):1421-6. PMID: 10871458.
  15. 15Meldrum DR. Ovulation induction protocols. Archives of pathology & laboratory medicine. 1992;116(4):406-9. PMID: 1558480.
  16. 16Ben-Rafael Z, et al. Dose of human menopausal gonadotropin influences the outcome of an in vitro fertilization program. Fertility and sterility. 1987;48(6):964-8. PMID: 3119377.
  17. 17Baer G, et al. Comparison of recombinant human luteinising hormone (r-hLH) and human menopausal gonadotropin (hMG) in assisted reproductive technology. Current medical research and opinion. 2003;19(2):83-8. PMID: 12740151.
  18. 18Marci R, et al. Follow-up of 32 hypothalamo-hypopituitary patients treated with pulsatile gonadotropin-releasing hormone or human menopausal gonadotropin. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 1999;13(6):375-81. PMID: 10685330.
  19. 19van Wely M, et al. Urofollitropin and ovulation induction. Treatments in endocrinology. 2005;4(3):155-65. PMID: 15898821.
  20. 20Olson JL, et al. Shortened luteal phase after ovulation induction with human menopausal gonadotropin and human chorionic gonadotropin. Fertility and sterility. 1983;39(3):284-91. PMID: 6402386.
  21. 21Daya S. Follicle-stimulating hormone versus human menopausal gonadotropin for in vitro fertilization: results of a meta-analysis. Hormone research. 1995;43(5):224-9. PMID: 7782055.
  22. 22Levy T, et al. Low- versus high-dose human menopausal gonadotropin in an in vitro fertilization-embryo transfer program. Journal of assisted reproduction and genetics. 1995;12(4):235-8. PMID: 7580018.
  23. 23Maroulis GB, et al. Prospective randomized study of human menotropin versus a follicular and a luteal phase gonadotropin-releasing hormone analog-human menotropin stimulation protocols for in vitro fertilization. Fertility and sterility. 1991;55(6):1157-64. PMID: 1903732.
  24. 24Gougeon A, et al. Influence of human menopausal gonadotropin on the recruitment of human ovarian follicles. Fertility and sterility. 1990;54(5):848-52. PMID: 2121553.
  25. 25Shoham Z, et al. Results of ovulation induction using human menopausal gonadotropin or purified follicle-stimulating hormone in hypogonadotropic hypogonadism patients. Fertility and sterility. 1991;56(6):1048-53. PMID: 1743320.
  26. 26Martinez AR, et al. Pregnancy rates after timed intercourse or intrauterine insemination after human menopausal gonadotropin stimulation of normal ovulatory cycles: a controlled study. Fertility and sterility. 1991;55(2):258-65. PMID: 1899393.
  27. 27Garcia JE, et al. Human menopausal gonadotropin/human chorionic gonadotropin follicular maturation for oocyte aspiration: phase I, 1981. Fertility and sterility. 1983;39(2):167-73. PMID: 6217993.
  28. 28Edelstein MC, et al. Equivalency of human menopausal gonadotropin and follicle-stimulating hormone stimulation after gonadotropin-releasing hormone agonist suppression. Fertility and sterility. 1990;53(1):103-6. PMID: 2104806.
  29. 29Grøndahl ML, et al. Differences in gene expression of granulosa cells from women undergoing controlled ovarian hyperstimulation with either recombinant follicle-stimulating hormone or highly purified human menopausal gonadotropin. Fertility and sterility. 2009;91(5):1820-30. PMID: 18439596.
  30. 30van de Weijer BH, et al. Compositional analyses of a human menopausal gonadotrophin preparation extracted from urine (menotropin). Identification of some of its major impurities. Reproductive biomedicine online. 2003;7(5):547-57. PMID: 14680547.
  31. 31Laufer N, et al. The use of high-dose human menopausal gonadotropin in an in vitro fertilization program. Fertility and sterility. 1983;40(6):734-41. PMID: 6228444.
  32. 32Garcia JE, et al. Human menopausal gonadotropin/human chorionic gonadotropin follicular maturation for oocyte aspiration: phase II, 1981. Fertility and sterility. 1983;39(2):174-9. PMID: 6401635.
  33. 33Bühler KF, et al. Comparative effectiveness of recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG HP) in assisted reproductive technology (ART) treatments: a non-interventional study in Germany. Reproductive biology and endocrinology : RB&E. 2021;19(1):90. PMID: 34134695.
  34. 34Edirisinghe WR, et al. Superovulation of mice with human menopausal gonadotropin or pure follicle-stimulating hormone in combination with human chorionic gonadotropin and the effects of oocyte aging on in vitro fertilization. Journal of in vitro fertilization and embryo transfer : IVF. 1986;3(5):314-8. PMID: 3097220.
  35. 35Seibel MM, et al. Ovulation induction in polycystic ovary syndrome with urinary follicle-stimulating hormone or human menopausal gonadotropin. Fertility and sterility. 1985;43(5):703-8. PMID: 3922800.
  36. 36Gadir AA, et al. The response of patients with polycystic ovarian disease to human menopausal gonadotropin therapy after ovarian electrocautery or a luteinizing hormone-releasing hormone agonist. Fertility and sterility. 1992;57(2):309-13. PMID: 1735480.
  37. 37Orvieto R, et al. Human menopausal gonadotropin versus highly purified-hMG in controlled ovarian hyperstimulation for in-vitro fertilisation: does purity improve outcome?. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 2010;26(10):733-5. PMID: 20500109.
  38. 38Chong AP, et al. Influence of weight in the induction of ovulation with human menopausal gonadotropin and human chorionic gonadotropin. Fertility and sterility. 1986;46(4):599-603. PMID: 3093282.
  39. 39Oride A, et al. Comparison of human menopausal gonadotropin stimulation with and without clomiphene for in-vitro fertilisation in poor-responders. Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology. 2015;35(2):163-7. PMID: 25058620.
  40. 40Abbasi R, et al. Cumulative ovulation rate in human menopausal/human chorionic gonadotropin-treated monkeys: "step-up" versus "step-down" dose regimens. Fertility and sterility. 1987;47(6):1019-24. PMID: 3109955.
  41. 41Diamond MP, et al. Comparison of ovarian response in the same women with the same or different lots of human menopausal gonadotropin. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology. 1992;6(2):135-9. PMID: 1502931.
  42. 42Venturoli S, et al. Human urinary follicle-stimulating hormone and human menopausal gonadotropin in induction of multiple follicle growth and ovulation. Fertility and sterility. 1986;45(1):30-5. PMID: 3080344.
  43. 43Alcivar AA, et al. Endocrine changes in beef heifers superovulated with follicle-stimulating hormone (FSH-P) or human menopausal gonadotropin. Journal of animal science. 1992;70(1):224-31. PMID: 1582910.
  44. 44Aboulghar MA, et al. Successful treatment of long-term unexplained infertility with gonadotropin-releasing hormone agonist analogue and human menopausal gonadotropin. Acta obstetricia et gynecologica Scandinavica. 1990;69(4):313-5. PMID: 2123068.
  45. 45Vermesh M, et al. Follicle-stimulating hormone is the main determinant of follicular recruitment and development in ovulation induction with human menopausal gonadotropin. American journal of obstetrics and gynecology. 1987;157(6):1397-402. PMID: 3122575.
  46. 46Xia X, et al. A cohort study of both human menopausal gonadotropin (HMG) and recombinant luteinizing hormone addition at early follicular stage in in vitro fertilization outcome: A STROBE-compliant study. Medicine. 2019;98(19):e15512. PMID: 31083194.
  47. 47Gleicher N, et al. Generic human menopausal gonadotropin (hMG) in place of more costly follicle-stimulating hormone (FSH) for routine ovulation induction. Journal of assisted reproduction and genetics. 2000;17(9):489-95. PMID: 11155320.
  48. 48Stokman PG, et al. Human chorionic gonadotropin in commercial human menopausal gonadotropin preparations. Fertility and sterility. 1993;60(1):175-8. PMID: 8513939.
  49. 49Venturoli S, et al. Induction of ovulation in polycystic ovary: human menopausal gonadotropin or human urinary follicle stimulating hormone?. International journal of fertility. 1987;32(1):66-70. PMID: 2880819.
  50. 50Benadiva CA, et al. Ovarian response to human menopausal gonadotropin following suppression with oral contraceptives. Fertility and sterility. 1988;50(3):516-8. PMID: 3137106.
  51. 51Takaya Y, et al. Minimum values for midluteal plasma progesterone and estradiol concentrations in patients who achieved pregnancy with timed intercourse or intrauterine insemination without a human menopausal gonadotropin. BMC research notes. 2018;11(1):61. PMID: 29357944.
  52. 52Pantos C, et al. Increasing the human menopausal gonadotropin dose--does the response really improve?. Fertility and sterility. 1990;53(3):436-9. PMID: 2106451.
  53. 53Rashidi M, et al. Advantages of recombinant follicle-stimulating hormone over human menopausal gonadotropin for ovarian stimulation in intrauterine insemination: a randomized clinical trial in unexplained infertility. European journal of obstetrics, gynecology, and reproductive biology. 2013;169(2):244-7. PMID: 23541417.
  54. 54Laufer N, et al. Delaying human chorionic gonadotropin administration in human menopausal gonadotropin-induced cycles decreases successful in vitro fertilization of human oocytes. Fertility and sterility. 1984;42(2):198-203. PMID: 6430722.
  55. 55Chaffkin LM, et al. A comparative analysis of the cycle fecundity rates associated with combined human menopausal gonadotropin (hMG) and intrauterine insemination (IUI) versus either hMG or IUI alone. Fertility and sterility. 1991;55(2):252-7. PMID: 1899392.
  56. 56Littman BA, et al. Human menopausal gonadotropin stimulation in monkeys: blockade of the luteinizing hormone surge by a highly transient ovarian factor. Fertility and sterility. 1984;41(3):440-7. PMID: 6421627.
  57. 57Yang TS, et al. Comparison of human menopausal gonadotropin and follicle-stimulating hormone with gonadotropin-releasing hormone agonist desensitization for controlled ovarian hyperstimulation in in vitro fertilization. Zhonghua yi xue za zhi = Chinese medical journal; Free China ed. 1995;55(6):452-6. PMID: 7634183.
  58. 58Serafini P, et al. Human chorionic gonadotropin reduces aromatizable androgens and aromatase activity in women stimulated by clomiphene citrate and human menopausal gonadotropin. American journal of obstetrics and gynecology. 1986;155(6):1236-9. PMID: 3098102.
  59. 59McFaul PB, et al. Treatment of clomiphene citrate-resistant polycystic ovarian syndrome with pure follicle-stimulating hormone or human menopausal gonadotropin. Fertility and sterility. 1990;53(5):792-7. PMID: 2110070.
  60. 60Plachot M, et al. Sequential use of clomiphene citrate, human menopausal gonadotropin, and human chorionic gonadotropin in human in vitro fertilization. I. Follicular growth and oocyte suitability. Fertility and sterility. 1985;43(2):255-62. PMID: 3917950.

We're not your doctor, and this isn't medical advice. It's a plain-English summary of what the research says, so you can have a smarter conversation with someone who is.

Keep up with this stuff

Want the rest of the peptide world, in plain English?

New breakdowns, safety updates, and what's actually worth your money. Free. Unsubscribe in one click.